These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25944034)

  • 1. Words of Wisdom. Re: incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.
    Butler P; Scovell JM; Ramasamy R; Lipshultz LI
    Eur Urol; 2015 Jun; 67(6):1186-7. PubMed ID: 25944034
    [No Abstract]   [Full Text] [Related]  

  • 2. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.
    Haider A; Zitzmann M; Doros G; Isbarn H; Hammerer P; Yassin A
    J Urol; 2015 Jan; 193(1):80-6. PubMed ID: 24980615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Words of wisdom: re: long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome:an observational, long-term registry study.
    Dohle GR
    Eur Urol; 2014 Nov; 66(5):965-6. PubMed ID: 25763444
    [No Abstract]   [Full Text] [Related]  

  • 4. Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register.
    Yassin A; Salman M; Talib RA; Yassin DJ
    Aging Male; 2017 Jun; 20(2):125-133. PubMed ID: 28282997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rational approach to androgen therapy for hypogonadal men with prostate cancer.
    Kaufman J
    Int J Impot Res; 2006; 18(1):26-31. PubMed ID: 16208401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone replacement therapy and the risk of prostate cancer.
    Warburton D; Hobaugh C; Wang G; Lin H; Wang R
    Asian J Androl; 2015; 17(6):878-81; discussion 880. PubMed ID: 25865848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone replacement therapy after primary treatment for prostate cancer.
    Agarwal PK; Oefelein MG
    J Urol; 2005 Feb; 173(2):533-6. PubMed ID: 15643240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Registry of Hypogonadism in Men (RHYME): design of a multi-national longitudinal, observational registry of exogenous testosterone use in hypogonadal men.
    Rosen RC; Wu FC; Behre HM; Roehrborn CG; Schröder FH; Siami FS; Martha JF; Finn JD; Araujo AB
    Aging Male; 2013 Mar; 16(1):1-7. PubMed ID: 23373674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry.
    Morales A
    BJU Int; 2011 May; 107(9):1369-73. PubMed ID: 21518230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
    Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
    J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone deficiency syndrome: treatment and cancer risk.
    Raynaud JP
    J Steroid Biochem Mol Biol; 2009 Mar; 114(1-2):96-105. PubMed ID: 19429438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
    BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical review 34: Androgen treatment of hypogonadal men.
    Bhasin S
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1221-5. PubMed ID: 1592862
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone administration in older men.
    Matsumoto AM
    Endocrinol Metab Clin North Am; 2013 Jun; 42(2):271-86. PubMed ID: 23702401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of continuous long-term testosterone therapy (TTh) on anthropometric, endocrine and metabolic parameters for up to 10 years in 115 hypogonadal elderly men: real-life experience from an observational registry study.
    Yassin AA; Nettleship J; Almehmadi Y; Salman M; Saad F
    Andrologia; 2016 Sep; 48(7):793-9. PubMed ID: 26762680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testosterone Therapy on Active Surveillance and Following Definitive Treatment for Prostate Cancer.
    Golla V; Kaplan AL
    Curr Urol Rep; 2017 Jul; 18(7):49. PubMed ID: 28589395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies.
    Saad F; Yassin A; Doros G; Haider A
    Int J Obes (Lond); 2016 Jan; 40(1):162-70. PubMed ID: 26219417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current topics in testosterone replacement of hypogonadal men.
    Nieschlag E
    Best Pract Res Clin Endocrinol Metab; 2015 Jan; 29(1):77-90. PubMed ID: 25617174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.